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Abstract
Background
Pneumonia is the leading cause of infectious death amongst children globally, with the high-
est burden in Africa. Early identification of children at risk of treatment failure in the commu-
nity and prompt referral could lower mortality. A number of clinical markers have been
independently associated with oral antibiotic failure in childhood pneumonia. This study
aimed to develop a prognostic model for fast-breathing pneumonia treatment failure in sub-
Saharan Africa.
Method
We prospectively followed a cohort of children (2–59 months), diagnosed by community
health workers with fast-breathing pneumonia using World Health Organisation (WHO) inte-
grated community case management guidelines. Cases were followed at days 5 and 14 by
study data collectors, who assessed a range of pre-determined clinical features for treat-
ment outcome. We built the prognostic model using eight pre-defined parameters, using
multivariable logistic regression, validated through bootstrapping.
Results
We assessed 1,542 cases of which 769 were included (32% ineligible; 19% defaulted). The
treatment failure rate was 15% at day 5 and relapse was 4% at day 14. Concurrent malaria
diagnosis (OR: 1.62; 95% CI: 1.06, 2.47) and moderate malnutrition (OR: 1.88; 95% CI:
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1.09, 3.26) were associated with treatment failure. The model demonstrated poor calibration
and discrimination (c-statistic: 0.56).
Conclusion
This study suggests that it may be difficult to create a pragmatic community-level prognostic
child pneumonia tool based solely on clinical markers and pulse oximetry in an HIV and
malaria endemic setting. Further work is needed to identify more accurate and reliable refer-
ral algorithms that remain feasible for use by community health workers.
Background
Globally, pneumonia is the leading infectious cause of death amongst children under five, with
an estimated 0.9 million deaths annually, and the highest burden found in Africa [1, 2]. While
there have been reductions in pneumonia mortality over the last decade and several cost-effec-
tive interventions are available, such as Haemophilus influenzae B (HiB) and pneumococcal
conjugate vaccines (PCV) [3, 4], effective care seeking and case management will still be needed
to significantly lower mortality.
The World Health Organisation (WHO) integrated community case management (iCCM)
guidelines clinically stratify pneumonia into either non-severe pneumonia (fast breathing only)
or severe pneumonia requiring referral (presence of chest indrawing or danger signs) [5]. Non-
severe cases—or ‘fast-breathing pneumonia’—are treated at home with oral antibiotics. Imple-
mentation of standardized treatment and referral guidelines has been associated with a 36%
reduction in pneumonia mortality [6]. A potential strategy to further reduce mortality among
children with fast-breathing pneumonia would be to identify those at risk of oral antibiotic
treatment failure and higher mortality rates [7], for early referral when they are potentially
more responsive to interventions.
Treatment failure is the persistence of symptoms or deterioration following antibiotic initi-
ation [8]. Common causes of treatment failure include incorrect initial diagnosis, host comor-
bidities such as HIV infection and malnutrition, and viral or antibiotic-resistant causative
organisms [9]. Several predictive tools have been developed to distinguish those children with
pneumonia who are at higher risk of adverse outcomes (i.e. treatment failure and death) [10,
11]. Factors commonly found to be associated with treatment failure are young age, fast
breathing, hypoxemia (or a peripheral oxygen saturation (SpO2)<90%) and poor antibiotic
adherence [12–16]. To date these studies have been predominantly focused at the hospital
level, among severe and very-severe pneumonia patients, the outcome of death, and used data
collected by facility-based healthcare workers. A recent literature review for risks of oral anti-
biotic treatment failure found a considerable evidence gap in understanding the predictors of
treatment failure at the community level and with fast-breathing pneumonia, specifically
from the African region [17].
A referral algorithm that could be implemented at the community-level (e.g. as an mHealth
tool) presents an opportunity for further reduction in pneumonia morbidity and mortality,
through more rapid referral of higher risk children when they are more amenable to alternative
treatments. The aim of this study was to develop a pragmatic prognostic algorithm for treat-
ment failure in children diagnosed with fast-breathing pneumonia by community health work-
ers (CHWs), treated with oral co-trimoxazole (the first line treatment during the study period)
in the community.
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Materials and Methods
Setting
We conducted a prospective cohort study in Malawi from September 2013 to June 2014, nested
within a larger parent study assessing the impact of PCV introduction in Malawi. This study
was conducted in sub-populations of two districts in the central region of Malawi (Mchinji and
Lilongwe). The populations covered were all rural, with mobile phone ownership of 35% and
the populations were predominantly subsistence farmers [18].
The primary health care system in rural Malawi consists of government employed CHWs,
called Health Surveillance Assistants locally. CHWs receive 12 weeks basic training delivered
by the government (including iCCM), and they run designated village clinics one or two times
per week as well as conducting house visits and outreach campaigns. These CHWs cover catch-
ment areas of approximately 1,200 people, although this varies according to region, and are
supervised by senior CHWs based at health facilities.
Data Collection
Patients were recruited at weekly village clinics run by 34 CHWs, 18 in Mchinji and 16 in
Lilongwe rural, with a catchment area of approximately 50,000 people and 8,500 children
under five. CHWs were responsible for the initial clinical assessment, following slightly modi-
fied iCCM guidelines with concurrent diagnoses and treatments allowed; in Malawi HIV and
malaria rapid diagnostic testing (RDTs) are not fully implemented at the community-level and
it is common for acute fevers to be presumptively treated as malaria [19]. This cohort of
CHWs had not been trained to conduct paediatric HIV or rapid malaria testing.
If diagnosed with pneumonia, information from the clinical assessment (including pulse
oximetry with Lifebox1) was recorded on case report forms (CRFs) by the CHW, along with
their referral or treatment decision. To measure PCV effectiveness, the parent PCV study
required a consistent clinical pneumonia definition applied across the community, health cen-
tre, and hospital health system levels. Therefore, the CHW CRFs included additional respira-
tory signs associated with more severe disease and routinely collected at the facility level, but
not previously included at the community level, including nasal flaring, head nodding, and
grunting. Pulse oximetry and the CRFs were introduced among these CHWs in late 2011 as
part of the parent PCV study and were also used for this sub-study, both are not currently stan-
dard care at this level in Malawi [20]–all other aspects of care were routine. CHWs had received
training on the CRFs, pulse oximetry and clinical assessments in 2011, and attended monthly
mentorship meetings and annual refresher trainings with local senior clinical staff in the two
years preceding and throughout this study, to ensure quality data collection. CRFs were pre-
printed with a unique barcode and were submitted monthly to the CHW supervisors who
checked and submitted them to research project staff. This data was entered into a Microsoft
Access database, with regular data cleaning and checking.
Although CHWs are recommended to follow up children after pneumonia treatment, this is
not done routinely in actual practice, and this study required routine, timely, and rigorous out-
come assessments. Community-level outcome assessments were not included in the parent
PCV study. For each village clinic, we therefore employed local village level data collectors
(VDCs) to recruit and conduct routine, timely, and comprehensive follow up interviews. VDCs
received training on conducting a clinical assessment for pneumonia signs and symptoms,
using a pulse oximeter, the study protocol and questionnaires. Clinical assessment training
included the use of videos, demonstrations, practical sessions and supervised assessments with
real cases at local health centres. All CHWs also attended the training. A one month field pilot
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(August 2013) was conducted, followed by a half day refresher training for all VDCs and
CHWs prior to study recruitment.
Patient recruitment was done by the VDCs at the village clinics (on ‘Day 0’). Patients were
eligible for recruitment if the CHW had diagnosed them with fast-breathing pneumonia and
prescribed oral antibiotics for home treatment. VDCs followed up patients at their homes on
day 5 and day 14. If the patient was not located on day 5, the VDCs re-visited the home on
day 7. At the follow up interviews, VDCs conducted a clinical assessment of the child (includ-
ing pulse oximetry), asked about additional care seeking and antibiotic adherence. We used
smart phones for follow up data collection, with data downloaded onto field supervisor’s lap-
tops every 2 weeks and cleaning checks run each month. Data was linked with the CHW filled
CRFs through the unique barcode, which the VDCs scanned to register a case at the village
clinic.
Several data quality assurance exercises were carried out to ensure reliable and consistent
data, including: 1) an initial vital signs standardization audit conducted by a paediatric pul-
monologist, which all VDCs passed. 2) Random GPS spot checks by field supervisors of fol-
low up locations. 3) All VDCs had at least one interview supervised by a pediatrician to
ensure standardized clinical assessments including oximetry, in which all performed satis-
factorily. 4) Monthly data review and feedback meetings, to highlight and address data qual-
ity issues. 5) Regular shadowing of interviews by field supervisors, with concurrent
recording of clinical signs. 6) Remote clinical validation for the presence of lower chest
indrawing from a random sample of VDC collected video clips.
Definitions
Cohort. all children aged 2–59 months with CHW-diagnosed WHO fast-breathing pneu-
monia who were adherent to home oral co-trimoxazole treatment. First line treatment for fast-
breathing pneumonia in Malawi is a 5-day BD (twice a day) course of co-trimoxazole (where a
dose is: 1/2 480mg tablet for 2–11 months; 1 480mg tablet for 12–59 months).
Fast-breathing pneumonia. defined according to the 2013 iCCM guidelines[5], as the
presence of cough or difficult breathing and fast breathing (>50 breaths per minute for infants
2–11 months;>40 breaths per minute for children 12–59 months), in the absence of any dan-
ger signs or lower chest indrawing. Danger signs were recorded based on caregiver report and
clinical observation by the CHWs at presentation, and included: vomiting everything, unable
to feed, convulsions in the previous 24 hours, sleepy or unconscious, SpO2<90%, and grunt-
ing, nasal flaring and head nodding as signs of severe respiratory distress. All children who
were severely malnourished (mid-upper arm circumference (MUAC)<11.5cm) were referred.
Treatment failure. defined as the presence of any of the following on day 5 of follow up
(the day after the final dose of antibiotics): fast breathing for age, axillary temperature
>37.5°C, lower chest indrawing, any danger sign (as defined above), change of antibiotic, hos-
pital admission or death (adapted from Fox et al. [21]). Change in antibiotic was based on
caregiver report, with a named antibiotic prescribed by any level of clinical staff, and where
possible visually verified by the VDC. VDCs had received training on common antibiotics and
their trade names, and this information was printed for them to take to interviews for
reference.
Adherence. defined as completing at least 80% of the prescribed antibiotics and con-
firmed by visual examination of remaining antibiotics by the VDC. We restricted the model
to ‘adherent’ children only, as non-adherence has been shown to be associated with treat-
ment failure in previous studies; the aim of this study was to make a referral tool based on
clinical presentation only.
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Analysis
We described the cohort, including levels of missing data. The following variables were deter-
mined a priori for inclusion in the prognostic model based on a literature and expert panel
review and practicality for use at the community level: oxygen saturation; respiratory rate;
fever (axillary temperature>38°C); malnutrition, as determined by MUAC measurements;
age; PCV-13 and pentavalent vaccination (including HiB). We also decided to include concur-
rent clinical malaria diagnosis. The continuous variables were categorized before inclusion into
the model, based on substantive knowledge as follows: oxygen saturation of SpO2 90–94% and
95%; MUAC as moderate malnutrition (11.5–13.5cm) and normal nutrition (13.5cm); age
as 2–5, 6–11, and 12–59 months; respiratory rate as fast (>50 breaths per minute for 2–11
months,>40 breath per minute for 12–59 months) and very fast breathing (>70 breaths per
minute for 2–11 months,>60 breath per minute for 12–59 months).
Multivariable logistic regression was used to create the prognostic model, retaining all pre-
defined risk variables. Missing data were imputed using multiple imputation with chained
equations [22], assuming that data was missing at random. The model equation was validated
through bootstrapping. Model performance was evaluated using: pseudo R2; the Hosmer-
Lemeshow goodness of fit test (p-value>0.05 indicates good fit); c-statistic (scale of 0.5–1.0,
with 1.0 being perfect discrimination); slope shrinkage in the internal validation (scale of 0.0–
1.0, with 1.0 indicating no over-fitting). Additional information is found in S1 Text. The
patient’s log odds of treatment failure as derived from the model equation were converted into
the probability that they failed treatment, using the following equation:
Probability of treatment failure ¼ expðbetaXÞ=ð1þ expðbetaXÞÞ
Sample size. The sample size calculation was based on the requirement of 10 treatment
failure cases per degree of freedom in the model, therefore with the eight candidate predictors
evaluated using 11 degrees of freedom, we required a sample of at least 110 treatment failures.
Sensitivity analyses. We performed sensitivity analyses to compare: 1) the baseline char-
acteristics between those lost to follow up and those included in the final analysis; 2) check for
outlying CHWs to determine whether data collection inaccuracies could give rise to spurious
prediction results. For baseline clinical observations we calculated the mean, standard devia-
tion, minimum, 25th percentile, median, 75th percentile and maximum values by CHW. CHWs
were flagged if for any variable, the 25th and 75th percentiles were equal and the model was re-
fit without the data from these CHWs. All descriptive analysis was done using Stata SE11 and
statistical analysis was done using R version 3.1.1 [23].
Ethics
Informed consent for study recruitment and prospective follow up was sought from the child’s
accompanying care-giver at the initial clinical assessment and was confirmed at each subse-
quent follow up with the care-giver present. The study information sheet was read aloud by the
VDC before starting the interview. Consent was given verbally and recorded in the electronic
form on the smart phone. Verbal consent was sought as literacy is low in this population. Ethi-
cal approval for this informed consent procedure and the overall study was granted by the
National Health Sciences Research Committee in Malawi (reference: 941).
Results
The VDCs assessed 1,542 children diagnosed with fast-breathing pneumonia by the CHWs for
enrollment over a 9 month period, of which 1,055 were eligible. Reasons for ineligibility were:
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presence of lower chest indrawing and/or danger signs (60%), no fast breathing (20%), children
were not given antibiotics (16%) or children were too old or too young (4%). A total of 197
children (19%) were lost to follow-up; Table 1 shows their baseline characteristics separately
from those with follow-up data. Among the 858 children with complete follow-up, we included
769 in the final analysis (Fig 1). Of these, 114 had treatment failure at day five of follow-up, a
risk of 14.8% (95% CI: 12.3 to 17.3). Of these treatment failure cases, 29 (25.4%) had not recov-
ered at day 14 and of those without treatment failure we observed an additional 25 children
with relapse at day 14 of follow up (3.8%; 95% CI: 2.8 to 6.2). The main reasons for being classi-
fied as a treatment failure case were: persistence of fast breathing (65%); grunting (12%); fever
(9%) and prescription of an alternative antibiotic (9%)—Table 2.
Odds ratios, following imputation for missing values, for the eight pre-defined predictors of
treatment failure are reported in Table 3. Concurrent clinical malaria diagnosis (aOR: 1.62;
95% CI: 1.06, 2.47) and moderate malnutrition (aOR: 1.88; 95% CI: 1.09, 3.26) were both signif-
icantly associated with treatment failure. The prediction model’s eight characteristics explained
Table 1. Baseline patient characteristics, including predictors of treatment failure for children
enrolled in the cohort by loss to follow-up (sensitivity analysis 1)
Characteristic Complete follow-up
(n = 769)
Lost to follow-up
(n = 197)
Mean (SD) Mean (SD)
Proportion (% missing) Proportion (% missing)
Age (months) 21.7 (14.7) 22.8 (14.9)
12 to 59 months 70.3% (0.9%) 75.1% (2.0%)
6 to 11 month 16.5% 13.0%
2 to 5 months 13.1% 11.9%
Respiratory rate: 2–11 months (breaths/
min)
56.2 (5.1) 57.1 (5.9)
12–59 months (breaths/min) 47.5 (7.1) 47.7 (5.8)
Very fast 1.1% (6.1%) 4.0% (7.1%)
Oxygen saturation (%) 96.4 (1.9) 96.7 (2.0)
Abnormal (90–94%) 15.3% (1.4%) 12.8% (0.5%)
Temperature (°C) 37.1 (1.0) 37.2 (1.0)
Fever 38°C 18.2% (4.2%) 19.8% (5.0%)
MUAC (cm) * 14.7 (1.4) 15.0 (1.4)
Moderately malnourished (<13.5 cm) 17.1% (19.5%) 10.1% (19.8%)
Proportion (% missing) Proportion (% missing)
District: Mchinji 45.5% (0%) 39.1% (0%)
Sex: Female 52.7% (2.0%) 52.6% (0.5%)
Pentavalent vaccine: 3 doses 92.5% (6.4%) 90.3% (6.1%)
PCV13 vaccination: 3 doses * 78.6% (23.0%) 65.9% (36.0%)
†Concurrent malaria diagnosis 40.2% (0.3%) -
The two study areas were in Mchinji and Lilongwe rural, both in the central region of Malawi. SD: standard
deviation; MUAC: mid-upper arm circumference; PCV13: 13-valent pneumococcal conjugate vaccine.
*p-value<0.05 using chi2 test or t-test.
†Concurrent diagnosis was conﬁrmed at follow-up so those lost to follow-up do not have this information.
Malaria diagnosis was clinical and made at the same time as the pneumonia diagnosis by the CHWs.
doi:10.1371/journal.pone.0136839.t001
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5.1% of the variation in the risk of treatment failure (R2 value). The model equation is:
Log odds of treatment failure
¼ 2:475 þ ðage 6 11 months x  0:315Þ þ ðage 2 5 months x 0:057Þ
þ ðvery fast breathing x 0:001Þ þ ðhypoxemia x 0:441Þ þ ðfever x  0:495Þ
þ ðmoderately malnourished x 0:633Þ þ ð1 2 doses pentavalent vaccine x
1:267Þ þ ð3 doses pentavalent vaccine x 0:189Þ þ ð1 2 doses PCV x 0:621Þ
þ ð3 doses PCV x 0:284Þ þ ðconcurrent malaria diagnosis x 0:480Þ
The predicted risk of treatment failure was plotted with a risk predictiveness curve (Fig 2).
The predicted risk of treatment failure increased gradually until the 80th percentile. The
observed risks of treatment failure for each quintile of predicted risk were plotted at the mid-
point of the quintile. Children in the highest-risk quartile were 3.19 times more likely to fail
Fig 1. Participant flow diagram for inclusion in the prognostic algorithmmodel.
doi:10.1371/journal.pone.0136839.g001
Predicting Treatment Failure in Children with Fast-Breathing Pneumonia
PLOS ONE | DOI:10.1371/journal.pone.0136839 August 27, 2015 7 / 15
oral co-trimoxazole than children in the lowest-risk quartile, a measure of discrimination. The
c-statistic (0.56 after bootstrap validation) demonstrated that the model had a low ability to
detect subtle differences or discriminate. We found evidence of adequate calibration as the
observed risks agreed approximately with the predicted risks for each quintile. However, the
Hosmer-Lemeshow goodness of fit test showed some evidence of lack of fit of the model
(P = 0.04).
If CHWs referred those children in the top risk quintile (i.e. any child who’s score indicated
a predicted risk80th percentile), 33.3% (95% CI: 24.4, 41.6) of the treatment failure cases
would be referred; this is the sensitivity. The same decision rule would result in a specificity of
82.4% (95% CI: 79.5, 85.3), a positive predictive value of 24.8% (95% CI: 18.0, 31.6) and nega-
tive predictive value of 87.7% (95% CI: 85.1, 90.3). While the sensitivity and specificity are
properties of the prediction model and the decision rule for referral, the predictive values
depend on the incidence of treatment failure in a given population and setting. Fig 3 gives a
worked example.
Based on the internal (statistical) validation, we found some evidence of over-fitting the
logistic model to the data because the slope-shrinkage statistic was 0.6. Fig 4 demonstrates the
discrepancy between the apparent and bootstrap-corrected curves. For the sensitivity analysis
of outlying CHWmeasurements, we found no CHWs with suspicious data.
Discussion
We found a treatment failure rate of 14.8% at day 5 of follow up, for fast-breathing pneumonia
treated with co-trimoxazole. This is consistent with rates found in previous studies of fast-
breathing pneumonia treatment failure with co-trimoxazole, with rates ranging from 11–21%,
Table 2. Distribution of World Health Organization criteria for diagnosing treatment failure at day 5 of
follow up
Treatment failure criteria Number (%)
(n = 114/769)
Treatment failure 114 (14.8%)
Fast Breathing† 74 (64.9%)
SpO2 <90% 7 (6.1%)
Axillary temperature >37.5°C 10 (8.8%)
Lower chest indrawing 6 (5.3%)
Danger signs: 26 (22.8%)
Vomiting everything 4 (3.5%)
Nasal Flaring 5 (4.4%)
Grunting 14 (12.3%)
Head nodding 0
Convulsions 2 (1.8%)
Sleepy/unconscious 1 (0.9%)
Unable to feed 2 (1.8%)
Admitted to hospital 2 (1.8%)
Prescribed alternative antibiotic 10 (8.8%)
‘Admitted to hospital’ and ‘prescribed alternative antibiotic’ were based on care giver report. SpO2:
peripheral oxygen saturation
Children fulﬁlling more than one criteria will appear more than once
†Fast breathing deﬁned as >50 breaths per minute in infants aged 2–11 months, and >40 breaths per
minute in children aged 12–59 months.
doi:10.1371/journal.pone.0136839.t002
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albeit from studies conducted in South Asia at the facility level, and not with CHWs [15, 24].
The model performed relatively poorly with a c-statistic of 0.56 and R2 of 5.1%. We found the
best predictors for failure were a concurrent clinical malaria diagnosis and moderate malnutri-
tion, while predictors such as young age and respiratory rate did not show any significant asso-
ciations. Possible explanations of our findings include: lack of key variables (e.g. HIV status
and laboratory-confirmed malaria); challenges in community diagnosis of pneumonia; and
quality of antibiotics, adherence and additional care seeking.
In the context of this stud y setting, we were unable to reliably or ethically collect HIV status
of the children included, as the study was implemented within an existing larger parent PCV13
effectiveness study. The cohort of CHWs that were originally selected to participate in the
wider study were not trained or qualified to provide HIV care or use RDTs for malaria testing,
something which is common in community settings. Prior studies have demonstrated that
Table 3. Predictors of treatment failure after multiple imputation: odds ratios and confidence
intervals.
Predictor Odds ratio (95% CI)
Age (grouped linear)
12 to 59 months 1.0
6 to 11 months 0.73 (0.39, 1.35)
2 to 5 months 1.06 (0.53, 2.12)
Respiratory rate (indicator)
Fast 1.0
Very fast 1.00 (0.48, 2.08)
Oxygen saturation (grouped linear)
Normal (95%) 1.0
Abnormal (90–94%) 1.55 (0.90, 2.67)
Fever (indicator)
No 1.0
Yes (38°C) 0.61 (0.34, 1.11)
MUAC (indicator)HYPERLINK *
Well nourished (13.5cm) 1.0
Moderately malnourished (<13.5cm) 1.88 (1.09, 3.26)
Pentavalent vaccination
No doses 1.0
1–2 doses 0.28 (0.02, 4.07)
3 doses 1.21 (0.34, 4.29)
PCV13 vaccination
No doses 1.0
1–2 doses 1.86 (0.26, 13.06)
3 doses 1.33 (0.62, 2.87)
Concurrent malaria diagnosis*
No 1.0
Yes 1.62 (1.06, 2.47)
CI: conﬁdence interval; MUAC: mid-upper arm circumference; PCV13: 13 valent pneumococcal conjugate
vaccine. ‘Fast’ respiratory rate was deﬁned as >50 breaths per minute for infants aged 2–11 months and
>40 breath per minute for 12-59months, and ‘very fast’ was >70 breaths per minute for infants aged 2–11
months and >60 breath per minute for 12-59months.
*p-value<0.05
doi:10.1371/journal.pone.0136839.t003
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being HIV-infected or -exposed increases the odds of treatment failure in pneumonia
(although these studies referred to severe pneumonia) [25, 26]. Malawi is considered a high
HIV setting, with 8.9% of adults living in rural areas HIV-infected [18]. Currently, co-trimoxa-
zole is given as a prophylaxis to HIV-infected infants; therefore some of the infants included in
our cohort may have been taking co-trimoxazole already when diagnosed with fast-breathing
pneumonia. Including HIV status in a prognostic model may improve its performance; how-
ever as the aim was to develop a tool that CHWs could feasibly implement in the field, includ-
ing HIV status was not appropriate or practical for this cohort of government-supported
CHWs. Ongoing work in Malawi suggests that closely supervised CHWs supported by the pri-
vate sector can provide high quality HIV services, including pediatric HIV testing, therefore
inclusion of HIV in prediction models may be more realistic in the near future for children
Fig 2. Risk predictiveness curve. The solid line indicates children’s predicted risk of treatment failure. For each quintile of predicted risk, we plotted the
observed risks of treatment failure (open circles). The agreement between the predicted and observed risks measures the calibration.
doi:10.1371/journal.pone.0136839.g002
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cared for by select groups of CHWs with enhanced support [27]. The generalizability and
acceptability of a model designed for use by rural CHWs that requires HIV status remains an
important question.
We found concurrent clinical malaria diagnosis to be a predictor of antibiotic treatment fail-
ure. A study fromMozambique found that malaria diagnosis was the strongest risk factor asso-
ciated with having an acute respiratory infection (ARI) diagnosis in infants [28]. Prior studies,
including in Malawi, have demonstrated considerable overlap between malaria and pneumonia
diagnosis based on clinical definitions, such as those used by the CHWs [29, 30]. A study from
Zambia demonstrated a decrease in concurrent malaria and fast-breathing pneumonia diagno-
ses from 87% to 28% with the introduction of malaria RDTs [31], emphasizing this issue. Clini-
cal diagnosis at the community level, especially in high HIV and malaria endemic areas, poses
a challenge to pneumonia case-management [32]. It is probable that our cohort of ‘fast-breath-
ing pneumonia’ patients included children with malaria who met the case definition for fast-
breathing pneumonia and were treated as such, explaining why a concurrent clinical malaria
diagnosis was associated with a poorer outcome. Future related work in malaria-endemic areas
should consider the use RDTs at the community-level for malaria diagnosis, even if this is not
routine amongst CHWs.
We excluded infants who were non-adherent from the analysis, based on information given
by the care-giver and where possible, visibly counting remaining tablets. However, in this set-
ting maternal education and literacy are low (35% completely illiterate [18]) and it is possible
that we retained non-adherent children through poor caregiver understanding and reporting,
and blood or urine testing for drug levels was not feasible. As we conducted this study in a
quasi-programmatic setting, an issue worth considering is counterfeit drugs, with some pilot
evidence that this is an issue in Malawi [33]. Adjusting for antibiotic quality and socio-eco-
nomic factors may improve the performance of a prognostic model, but again would be
impractical to include in a community-level referral tool.
Fig 3. Example of calculating probability of treatment failure.
doi:10.1371/journal.pone.0136839.g003
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This study had many strengths, in that it was a prospective community-based cohort imple-
mented in a quasi-programmatic setting, generating evidence not only on outcomes but also
the practicality of developing a reliable pragmatic prognostic without laboratory support. It
also included the use of pulse oximetry at the CHW level to support diagnosis and referral deci-
sion-making. However, our key limitations were the lack of HIV and malaria testing and rela-
tively high loss to follow-up, despite dedicated VDCs. Cases were recruited into the cohort
during village clinics, where the VDCs would arrange to visit the patient’s house for follow up.
Despite VDCs being recruited from the local area, there were issues in locating households,
and families being unavailable. The challenges with the active follow-up, included: lack of con-
sistent address information; people using multiple names; follow ups taking place over the
Fig 4. Observed and predicted treatment failure. The dotted line plots the observed vs. predicted probability of treatment failure the solid line is a bias-
corrected version (40 bootstrap repetitions). The rug plot along the top of the graph indicates the distribution of the predicted probabilities.
doi:10.1371/journal.pone.0136839.g004
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rainy season making travel challenging, and during planting and harvesting time when care-
givers were busy farming. Table 1 demonstrates there were some statistically significant differ-
ences at baseline between those with and without completed follow up, namely PCV13 receipt
and moderate malnutrition. Those children lost to follow up were marginally better nourished,
but had lower PCV13 coverage so it is unclear if having included these children would have
changed the model. However, the model retained a sufficient number of treatment failures in
relation to degrees of freedom; therefore, we do not think the high loss to follow-up detracts
from the findings but rather highlights the difficulty of working in rural communities in a pro-
grammatic setting.
We have learnt several lessons in attempting to prospectively evaluate risks of treatment fail-
ure in clinically diagnosed pneumonia at the community level. Firstly, the reliability of CHW
clinical diagnosis and treatment/referral decisions is a challenge and, despite active mentorship,
misclassification and therefore incorrect treatment was common. Malawi guidelines do allow
for CHWs to provide HIV testing services and recommend the use of RDTs but this is only
realistically implemented with private support. Nevertheless, to address these challenges future
studies should consider recruiting cohorts from higher levels of the healthcare system with
access to malaria testing, HIV status and more qualified healthcare staff, although this may
limit generalizability to the community setting. Secondly, our choice of VDCs was based on
their local knowledge of the communities and not on clinical experience; in spite of this, we
still had high loss to follow-up. Future studies could consider incentivizing care-givers to return
to the healthcare facility for follow-up assessments as active community-based follow-up poses
complex challenges, despite significant efforts. As co-trimoxazole is no longer the WHO rec-
ommendation for outpatient pneumonia treatment and newly revised guidelines allow for
home treatment of children with lower chest indrawing, further research on the performance
of a prognostic algorithm is needed.
While we have hypothesized several reasons for our findings, there is a lack of evidence
around rates, causes and predictors of treatment failure in fast-breathing pneumonia at the
community level in sub-Saharan Africa, with which to compare this study [17]. The differing
etiologies, epidemiology and distribution of socio-economic risk factors between a rural sub-
Saharan setting and South Asia [34], make it plausible that drivers of treatment failure (and
therefore the predictors) would also be different. The potential for enhancing referral algo-
rithms at the community level is exciting, but further work is needed to generate models with
greater sensitivity.
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